Journal for ImmunoTherapy of Cancer (Nov 2023)

1372 TriTCE Co-Stim: a novel trispecific T cell engager platform, with integrated CD28 costimulation, engineered to widen the therapeutic window for treatment of poorly infiltrated tumors

Maya Poffenberger,
Nichole Escalante,
Diego Perez Escanda,
Nina Weisser,
Thomas Spreter von Kreudenstein,
Lisa Newhook,
Purva Bhojane,
Peter Repenning,
Desmond Lau,
Polly Shao,
Alec Robinson,
Kesha Patel,
Alexandra Livernois,
Chayne L Piscitelli,
Nicole Afacan

Affiliations

Maya Poffenberger: Zymeworks BC Inc., Vancouver, BC, Canada
Nichole Escalante: Zymeworks BC Inc., Vancouver, BC, Canada
Diego Perez Escanda: Zymeworks BC Inc., Vancouver, BC, Canada
Nina Weisser: Zymeworks BC Inc., Vancouver, BC, Canada
Thomas Spreter von Kreudenstein: Zymeworks BC Inc., Vancouver, BC, Canada
Lisa Newhook: Zymeworks BC Inc., Vancouver, BC, Canada
Purva Bhojane: Zymeworks BC Inc., Vancouver, BC, Canada
Peter Repenning: Zymeworks BC Inc., Vancouver, BC, Canada
Desmond Lau: Zymeworks BC Inc., Vancouver, BC, Canada
Polly Shao: Zymeworks BC Inc., Vancouver, BC, Canada
Alec Robinson: Zymeworks BC Inc., Vancouver, BC, Canada
Kesha Patel: Zymeworks BC Inc., Vancouver, BC, Canada
Alexandra Livernois: Zymeworks BC Inc., Vancouver, BC, Canada
Chayne L Piscitelli: Zymeworks BC Inc., Vancouver, BC, Canada
Nicole Afacan: Zymeworks BC Inc., Vancouver, BC, Canada

DOI: https://doi.org/10.1136/jitc-2023-SITC2023.1372
Journal volume & issue: Vol. 11, no. Suppl 1

Abstract

No abstracts available.

Published in Journal for ImmunoTherapy of Cancer

ISSN: 2051-1426 (Online)
Publisher: BMJ Publishing Group
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://jitc.bmj.com

About the journal